POSITIVE Study Findings Shift Conversations on Pregnancy in ER+ Breast CancerJanuary 6th 2023
Jamie Carroll, APRN, CNP, MSN, weighs in on how findings from the POSITIVE study may change dialogue surrounding pregnancy for women with estrogen receptor–positive breast cancer who wish to pause adjuvant therapy.
Frontline Pola-R-CHP, CAR-T Second-Line Therapy Are Not Cost-Effective Choices For Patients With DLBCLJanuary 5th 2023
An economic analysis showed that neither polatuzumab vedotin nor CD19-directed CAR T-cell therapy are likely to be the most cost-effective for patients with diffuse large B-cell lymphoma based on their high costs and current long-term survival estimates.
Antidiarrheal Prophylaxis Remains a Key Focus in TKI Treatment for Patients with HER2+ Breast CancerJanuary 4th 2023
Loperamide prophylaxis was linked to low rates of grade 3 diarrhea in patients receiving adjuvant pyrotinib, but better antidiarrheal prophylaxis options are still needed in this setting.
Glofitamab Induces Promising Complete Response Rate in Relapsed/Refractory Diffuse Large B-Cell LymphomaJanuary 4th 2023
Glofitamab, an investigational CD20xCD3 T-cell engaging bispecific antibody, elicited encouraging response rates in patients with relapsed/refractory diffuse large B-cell lymphoma in a phase 1/2 study.
Black Women With HR+ Breast Cancer Experience Inferior Outcomes, Despite Comparable Recurrence ScoresJanuary 1st 2023
Non-Hispanic Black patients with hormone receptor (HR)–positive/HER2-negative breast cancer were more likely to have worse outcomes vs non-Hispanic White, Asian, and Hispanic patients, even with similar 21-gene recurrence scores.
Rucaparib Maintenance Extends Progression-Free Survival in Advanced Ovarian CancerDecember 30th 2022
Maintenance therapy with rucaparib monotherapy improved progression-free survival compared with placebo. However, the treatment also significantly elevated anemia and neutropenia rates in this setting.
Frontline Durvalumab Does Not Elicit Significant OS Improvement in Advanced, PD-L1-High NSCLCDecember 29th 2022
In the PEARL trial, monotherapy with durvalumab did not deliver a statistically significant improvement in overall survival vs platinum-based chemotherapy as frontline treatment in patients with PD-L1-high stage IV non–small cell lung cancer.
Opinion: Self-Care Is Key to Preserve Mental and Emotional Wellness for Oncology NursesDecember 28th 2022
Oncology nurses work in a setting that might exacerbate any underlying mental health problems. Although getting through a shift may feel like the main goal, self-care and resiliency is equally important for the RN.
Survivorship Clinic Visits Hold Answer to Questions About Post-Cancer PregnanciesDecember 27th 2022
Ellen Miller, MSN, FNP-BC, a nurse practitioner who specializes in survivorship care, underscores what conversations surrounding fertility and pregnancy may look like after radiation.
Grace Choong and Matthew Goetz On the Impact of Adjuvant Endocrine Therapy Omission in ER+ Positive Breast CancerDecember 26th 2022
Grace Choong, MD; and Matthew Goetz, MD, discuss the effect of omitting adjuvant endocrine therapy for patients with estrogen receptor–positive breast cancer who were treated with neoadjuvant chemotherapy.
Second-Line Liso-Cel Continues to Improve Event-Free Survival in Large B-Cell LymphomaDecember 25th 2022
In the second line setting, lisocabtagene maraleucel (liso-cel; Breyanzi) significantly reduced the risk of an event for patients with high-risk relapsed/refractory large B-cell lymphoma, compared with standard-of-care chemoimmunotherapy induction.
Camizestrant Emerges As A Potentially Effective Oral SERD for Patients With HER2-Negative Advanced Breast CancerDecember 24th 2022
Camizestrant doubled progression-free survival compared with fulvestrant in patients with estrogen receptor–positive, HER2-negative advanced breast cancer.
Adjuvant T-DM1 With Concurrent Radiotherapy Is Not Associated with Cardiotoxic Concerns in Early-Stage HER2+ Breast CancerDecember 23rd 2022
Patients with early-stage, HER2-positive breast cancer who received both adjuvant ado-trastuzumab emtansine and concurrent radiotherapy did not experience a significant drop in ejection fraction or global longitudinal strain.